Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

Nutrition Metabolism and Cardiovascular Diseases(2025)10.1016/j.numecd.2025.104036Source: DataRank Database

The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial is a research paper published in Nutrition Metabolism and Cardiovascular Diseases (2025). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

7 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: closedTopics (49)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (21)

Venkat Sanjay Manubolu,Jairo Aldana-Bitar ORCID,Suraj Dahal ORCID,Dhiran Verghese ORCID,Luay Alalawi ORCID

Live enrichment

PubMed:40287313

Novo Nordisk Foundation

Grant: unidentified

unidentified

National Institutes of Health

Novo Nordisk Foundation

Nortel Networks Inc

Novo Nordisk

General Electric

closedLicense: Elsevier TDM

https://doi.org/10.1016/j.numecd.2025.104036

https://pubmed.ncbi.nlm.nih.gov/40287313

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

LiverHumansFatty LiverDiabetes Mellitus, Type 2Hypoglycemic AgentsTomography, X-Ray ComputedTreatment OutcomeDouble-Blind MethodPredictive Value of TestsTime FactorsAgedMiddle AgedFemaleMaleAdiposityGlucagon-Like Peptide 1Glucagon-Like PeptidesCoronary Artery DiseaseSemaglutide

Keywords

Hepatocellular carcinoma (HCC)Randomized TrialCardiovascular Disease (Cvd)Computed Tomography Angiography (Cta)Coronary Artery Calcium (Cac)SemaglutideAtherosclerotic Cardiovascular Disease (Ascvd)Glp1 Receptor AgonistsMetabolic Dysfunction-associated Steatohepatitis (Mash)Metabolic Dysfunction-associated Steatotic Liver Disease (Masld)MaleTime FactorsGlucagon-Like PeptidesCoronary Artery DiseaseMiddle AgedFatty LiverTreatment OutcomeDiabetes Mellitus, Type 2LiverDouble-Blind MethodPredictive Value of TestsGlucagon-Like Peptide 1HumansHypoglycemic AgentsFemaleTomography, X-Ray ComputedAgedAdiposity